Apoptosis/NN
and/CC
growth/NN
inhibition/NN
in/IN
malignant/JJ
lymphocytes/NNS
after/IN
treatment/NN
with/IN
arsenic/JJ
trioxide/NN
at/IN
clinically/RB
achievable/JJ
concentrations/NNS
[/(
see/VB
comments/NNS
]/)

BACKGROUND/NN
:/:
Arsenic/JJ
trioxide/NN
(/(
As2O3/NN
)/)
can/MD
induce/VB
clinical/JJ
remission/NN
in/IN
patients/NNS
with/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
via/IN
induction/NN
of/IN
differentiation/NN
and/CC
programmed/VBN
cell/NN
death/NN
(/(
apoptosis/NN
)/)
./.
=====
We/PRP
investigated/VBD
the/DT
effects/NNS
of/IN
As2O3/NN
on/IN
a/DT
panel/NN
of/IN
malignant/JJ
lymphocytes/NNS
to/TO
determine/VB
whether/IN
growth-inhibitory/JJ
and/CC
apoptotic/JJ
effects/NNS
of/IN
As2O3/NN
can/MD
be/VB
observed/VBN
in/IN
these/DT
cells/NNS
at/IN
clinically/RB
achievable/JJ
concentrations/NNS
./.
=====
METHODS/NNS
:/:
Eight/CD
malignant/JJ
lymphocytic/JJ
cell/NN
lines/NNS
and/CC
primary/JJ
cultures/NNS
of/IN
lymphocytic/JJ
leukemia/NN
and/CC
lymphoma/NN
cells/NNS
were/VBD
treated/VBN
with/IN
As2O3/NN
,/,
with/IN
or/CC
without/IN
dithiothreitol/NN
(/(
DTT/NN
)/)
or/CC
buthionine/NN
sulfoximine/NN
(/(
BSO/NN
)/)
(/(
an/DT
inhibitor/NN
of/IN
glutathione/NN
synthesis/NN
)/)
./.
=====
Apoptosis/NN
was/VBD
assessed/VBN
by/IN
cell/NN
morphology/NN
,/,
flow/NN
cytometry/NN
,/,
annexin/NN
V/NN
protein/NN
level/NN
,/,
and/CC
terminal/JJ
deoxynucleotidyl/NN
transferase/NN
labeling/NN
of/IN
DNA/NN
fragments/NNS
./.
=====
Cellular/JJ
proliferation/NN
was/VBD
determined/VBN
by/IN
5-bromo-2'-deoxyuridine/NN
incorporation/NN
into/IN
DNA/NN
and/CC
flow/NN
cytometry/NN
and/CC
by/IN
use/NN
of/IN
a/DT
mitotic/JJ
arrest/NN
assay/NN
./.
=====
Mitochondrial/JJ
transmembrane/JJ
potential/NN
(/(
delta/NN
psi(m)/NN
)/)
was/VBD
measured/VBN
by/IN
means/NNS
of/IN
rhodamine/NN
123/CD
staining/NN
and/CC
flow/NN
cytometry/NN
./.
=====
Protein/NN
expression/NN
was/VBD
assessed/VBN
by/IN
western/NN
blot/NN
analysis/NN
or/CC
immunofluorescence/NN
./.
=====
RESULTS/NNS
:/:
Therapeutic/JJ
concentrations/NNS
of/IN
As2O3/NN
(/(
1-2/CD
microM/NN
)/)
had/VBD
dual/JJ
effects/NNS
on/IN
malignant/JJ
lymphocytes/NNS
:/:
1/LS
)/)
inhibition/NN
of/IN
growth/NN
through/IN
adenosine/NN
triphosphate/NN
(/(
ATP/NN
)/)
depletion/NN
and/CC
prolongation/NN
of/IN
cell/NN
cycle/NN
time/NN
and/CC
2/LS
)/)
induction/NN
of/IN
apoptosis/NN
./.
=====
As2O3-induced/JJ
apoptosis/NN
was/VBD
preceded/VBN
by/IN
delta/NN
psi(m)/NN
collapse/NN
./.
=====
DTT/NN
antagonized/VBD
and/CC
BSO/NN
enhanced/VBD
As2O3-induced/JJ
ATP/NN
depletion/NN
,/,
delta/NN
psi(m)/NN
collapse/NN
,/,
and/CC
apoptosis/NN
./.
=====
Caspase-3/NN
activation/NN
,/,
usually/RB
resulting/VBG
from/IN
delta/NN
psi(m)/NN
collapse/NN
,/,
was/VBD
not/RB
always/RB
associated/VBN
with/IN
As2O3-induced/JJ
apoptosis/NN
./.
=====
As2O3/NN
induced/VBD
PML/NN
(/(
promyelocytic/JJ
leukemia/NN
)/)
protein/NN
degradation/NN
but/CC
did/VBD
not/RB
modulate/VB
expression/NN
of/IN
cell/NN
cycle-related/JJ
proteins/NNS
,/,
including/VBG
c-myc/NN
,/,
retinoblastoma/NN
protein/NN
,/,
cyclin-dependent/JJ
kinase/NN
4/CD
,/,
cyclin/NN
D1/NN
,/,
and/CC
p53/NN
,/,
or/CC
expression/NN
of/IN
differentiation-related/JJ
antigens/NNS
./.
=====
CONCLUSIONS/NNS
:/:
Substantial/JJ
growth/NN
inhibition/NN
and/CC
apoptosis/NN
without/IN
evidence/NN
of/IN
differentiation/NN
were/VBD
induced/VBN
in/IN
most/JJS
malignant/JJ
lymphocytic/JJ
cells/NNS
treated/VBN
with/IN
1-2/CD
microM/NN
As2O3/NN
./.
=====
As2O3/NN
may/MD
prove/VB
useful/JJ
in/IN
the/DT
treatment/NN
of/IN
malignant/JJ
lymphoproliferative/JJ
disorders/NNS
./.